MIE-101 is based on the plant virus cowpea mosaic virus (CPMV) which is infectious to certain plants but not to animals including mice, dogs and humans.  CPMV does however resemble features of mammalian viruses, including its outer protein structure and its genetic nucleic acid, both components of which are recognized by the innate immune system through pattern recognition receptors (PRRs) .  The plant viral nanoparticle is directly administered into the tumor to activate the immune system within and elicit local and system anti-tumor immunity

Cancer treatments for humans can also be beneficial for veterinary applications including the treatment of companion animals with cancer.  Mosaic IE's lead veterinary compound MIE-201 has demonstrated promising antitumor effects in combination with radiation in dogs with spontaneous melanoma.  These studies are continuing and other potential veterinary applications are currently being evaluated.  These initial findings support further evaluation and development of MIE-201 for veterinary applications as a part of the company's commercialization plans. To learn more about our companion animal treatment platform and plans, please visit the Mosaic ImmunoEngineering Animal Health website.

The emergence of COVID-19, caused by SARS-CoV-2, highlights the need for a vaccine platform that enables rapid antigen discovery and vaccine development.  Nanotechnology provides an innovative approach to vaccine development by producing nanoparticles capable of mimicking viral structures and supporting next-generation vaccine design.

​

​

​

​

​

​